Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

New oral SLE therapy GL-701 awarded fast track designation

April 5, 1999

Cypress Bioscience closes partnership agreement with Fresenius

April 5, 1999

Celecoxib is an effective antipyretic agent in man

March 26, 1999

Celgene synthesizes potent TNF-alpha and PDE4 inhibitors

March 26, 1999

FDA grants orphan drug status to recombinant Pharming product

March 26, 1999

Inhibitors of MCP-1 disclosed by Zeneca for inflammation

March 25, 1999

Amgen patents novel hydroxamic acid-based MMP inhibitors

March 22, 1999

Pfizer discloses selective hydroxamic acid-based MMP-13 inhibitors

March 19, 1999

FDA approves Prosorba Column for use in rheumatoid arthritis

March 18, 1999

Celgene describes new series for reducing TNF-alpha levels

March 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...